Aethlon Medical Net Income 2006-2019 | AEMD

Aethlon Medical net income from 2006 to 2019. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Aethlon Medical Annual Net Income
(Millions of US $)
2019 $-6
2018 $-6
2017 $-7
2016 $-5
2015 $-7
2014 $-13
2013 $-5
2012 $-8
2011 $-6
2010 $-5
2009 $-6
2008 $-4
2007 $-6
2006 $-3
2005 $-2
Aethlon Medical Quarterly Net Income
(Millions of US $)
Q2 2019 $-2
Q1 2019 $-2
Q4 2019 $-2
Q3 2018 $-2
Q2 2018 $-1
Q1 2018 $-1
Q4 2018 $-1
Q3 2017 $-1
Q2 2017 $-1
Q1 2017 $-2
Q4 2017 $-2
Q3 2016 $-1
Q2 2016 $-2
Q1 2016 $-2
Q4 2016 $-1
Q3 2015 $-1
Q2 2015 $-1
Q1 2015 $-1
Q4 2015 $-1
Q3 2014 $-2
Q2 2014 $-1
Q1 2014 $-4
Q4 2014 $-7
Q3 2013 $-2
Q2 2013 $-3
Q1 2013 $-0
Q4 2013 $-3
Q3 2012 $0
Q2 2012 $-1
Q1 2012 $-1
Q4 2012 $-4
Q3 2011 $-1
Q2 2011 $-0
Q1 2011 $-3
Q4 2011 $2
Q3 2010 $-2
Q2 2010 $-3
Q1 2010 $-3
Q4 2010 $-1
Q3 2009 $-1
Q2 2009 $-1
Q1 2009 $-1
Q4 2009 $-1
Q3 2008 $-2
Q2 2008 $-2
Q1 2008 $-1
Q4 2008 $-1
Q3 2007 $-3
Q2 2007 $-0
Q1 2007 $-1
Q4 2007 $-4
Q3 2006 $-1
Q2 2006 $-1
Q1 2006 $-1
Q4 2006 $-1
Q3 2005 $-1
Q2 2005 $-1
Q1 2005 $-1
Q4 2005 $-1
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.004B $0.000B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $265.456B 19.34
Anthem (ANTM) United States $72.334B 15.87
Humana (HUM) United States $46.103B 19.12
Centene (CNC) United States $25.233B 13.92
WellCare Health Plans (WCG) United States $16.287B 21.39
Molina Healthcare (MOH) United States $8.358B 10.39
Select Medical Holdings (SEM) United States $3.087B 20.34
Magellan Health (MGLN) United States $1.970B 46.81
Triple-S Management (GTS) United States $0.469B 6.93
Joint (JYNT) United States $0.239B 86.30